Summary
According to APO Research, The global Colorectal Cancer Molecular Diagnostics market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Colorectal Cancer Molecular Diagnostics is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Asia-Pacific market for Colorectal Cancer Molecular Diagnostics is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for Colorectal Cancer Molecular Diagnostics is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Europe market for Colorectal Cancer Molecular Diagnostics is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The major global companies of Colorectal Cancer Molecular Diagnostics include Roche Diagnostics, Abbott, Thermo Fisher, Qiagen, Illumina, Biomerieux, Bio-Rad, Agilent and Daangene, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for Colorectal Cancer Molecular Diagnostics, market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Colorectal Cancer Molecular Diagnostics, also provides the revenue of main regions and countries. Of the upcoming market potential for Colorectal Cancer Molecular Diagnostics, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Colorectal Cancer Molecular Diagnostics revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Colorectal Cancer Molecular Diagnostics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Colorectal Cancer Molecular Diagnostics revenue, projected growth trends, production technology, application and end-user industry.
Colorectal Cancer Molecular Diagnostics segment by Company
Roche Diagnostics
Abbott
Thermo Fisher
Qiagen
Illumina
Biomerieux
Bio-Rad
Agilent
Daangene
Amoydx
Colorectal Cancer Molecular Diagnostics segment by Type
Polymerase Chain Reaction PCR
Molecular Hybridization
Biochip
Others
Colorectal Cancer Molecular Diagnostics segment by Application
Hospital
Third-Party Testing Agency
Others
Colorectal Cancer Molecular Diagnostics segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Colorectal Cancer Molecular Diagnostics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Colorectal Cancer Molecular Diagnostics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Colorectal Cancer Molecular Diagnostics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Colorectal Cancer Molecular Diagnostics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Colorectal Cancer Molecular Diagnostics company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Colorectal Cancer Molecular Diagnostics revenue, gross margin, and recent development, etc.
Chapter 8: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: Middle East, Africa, and Latin America type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
1 Market Overview
1.1 Product Definition
1.2 Colorectal Cancer Molecular Diagnostics Market by Type
1.2.1 Global Colorectal Cancer Molecular Diagnostics Market Size by Type, 2019 VS 2023 VS 2030
1.2.2 Polymerase Chain Reaction PCR
1.2.3 Molecular Hybridization
1.2.4 Biochip
1.2.5 Others
1.3 Colorectal Cancer Molecular Diagnostics Market by Application
1.3.1 Global Colorectal Cancer Molecular Diagnostics Market Size by Application, 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Third-Party Testing Agency
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Colorectal Cancer Molecular Diagnostics Market Dynamics
2.1 Colorectal Cancer Molecular Diagnostics Industry Trends
2.2 Colorectal Cancer Molecular Diagnostics Industry Drivers
2.3 Colorectal Cancer Molecular Diagnostics Industry Opportunities and Challenges
2.4 Colorectal Cancer Molecular Diagnostics Industry Restraints
3 Global Growth Perspective
3.1 Global Colorectal Cancer Molecular Diagnostics Market Perspective (2019-2030)
3.2 Global Colorectal Cancer Molecular Diagnostics Growth Trends by Region
3.2.1 Global Colorectal Cancer Molecular Diagnostics Market Size by Region: 2019 VS 2023 VS 2030
3.2.2 Global Colorectal Cancer Molecular Diagnostics Market Size by Region (2019-2024)
3.2.3 Global Colorectal Cancer Molecular Diagnostics Market Size by Region (2025-2030)
4 Competitive Landscape by Players
4.1 Global Colorectal Cancer Molecular Diagnostics Revenue by Players
4.1.1 Global Colorectal Cancer Molecular Diagnostics Revenue by Players (2019-2024)
4.1.2 Global Colorectal Cancer Molecular Diagnostics Revenue Market Share by Players (2019-2024)
4.1.3 Global Colorectal Cancer Molecular Diagnostics Players Revenue Share Top 10 and Top 5 in 2023
4.2 Global Colorectal Cancer Molecular Diagnostics Key Players Ranking, 2022 VS 2023 VS 2024
4.3 Global Colorectal Cancer Molecular Diagnostics Key Players Headquarters & Area Served
4.4 Global Colorectal Cancer Molecular Diagnostics Players, Product Type & Application
4.5 Global Colorectal Cancer Molecular Diagnostics Players Commercialization Time
4.6 Market Competitive Analysis
4.6.1 Global Colorectal Cancer Molecular Diagnostics Market CR5 and HHI
4.6.2 Global Top 5 and 10 Colorectal Cancer Molecular Diagnostics Players Market Share by Revenue in 2023
4.6.3 2023 Colorectal Cancer Molecular Diagnostics Tier 1, Tier 2, and Tier 3
5 Colorectal Cancer Molecular Diagnostics Market Size by Type
5.1 Global Colorectal Cancer Molecular Diagnostics Revenue by Type (2019 VS 2023 VS 2030)
5.2 Global Colorectal Cancer Molecular Diagnostics Revenue by Type (2019-2030)
5.3 Global Colorectal Cancer Molecular Diagnostics Revenue Market Share by Type (2019-2030)
6 Colorectal Cancer Molecular Diagnostics Market Size by Application
6.1 Global Colorectal Cancer Molecular Diagnostics Revenue by Application (2019 VS 2023 VS 2030)
6.2 Global Colorectal Cancer Molecular Diagnostics Revenue by Application (2019-2030)
6.3 Global Colorectal Cancer Molecular Diagnostics Revenue Market Share by Application (2019-2030)
7 Company Profiles
7.1 Roche Diagnostics
7.1.1 Roche Diagnostics Comapny Information
7.1.2 Roche Diagnostics Business Overview
7.1.3 Roche Diagnostics Colorectal Cancer Molecular Diagnostics Revenue and Gross Margin (2019-2024)
7.1.4 Roche Diagnostics Colorectal Cancer Molecular Diagnostics Product Portfolio
7.1.5 Roche Diagnostics Recent Developments
7.2 Abbott
7.2.1 Abbott Comapny Information
7.2.2 Abbott Business Overview
7.2.3 Abbott Colorectal Cancer Molecular Diagnostics Revenue and Gross Margin (2019-2024)
7.2.4 Abbott Colorectal Cancer Molecular Diagnostics Product Portfolio
7.2.5 Abbott Recent Developments
7.3 Thermo Fisher
7.3.1 Thermo Fisher Comapny Information
7.3.2 Thermo Fisher Business Overview
7.3.3 Thermo Fisher Colorectal Cancer Molecular Diagnostics Revenue and Gross Margin (2019-2024)
7.3.4 Thermo Fisher Colorectal Cancer Molecular Diagnostics Product Portfolio
7.3.5 Thermo Fisher Recent Developments
7.4 Qiagen
7.4.1 Qiagen Comapny Information
7.4.2 Qiagen Business Overview
7.4.3 Qiagen Colorectal Cancer Molecular Diagnostics Revenue and Gross Margin (2019-2024)
7.4.4 Qiagen Colorectal Cancer Molecular Diagnostics Product Portfolio
7.4.5 Qiagen Recent Developments
7.5 Illumina
7.5.1 Illumina Comapny Information
7.5.2 Illumina Business Overview
7.5.3 Illumina Colorectal Cancer Molecular Diagnostics Revenue and Gross Margin (2019-2024)
7.5.4 Illumina Colorectal Cancer Molecular Diagnostics Product Portfolio
7.5.5 Illumina Recent Developments
7.6 Biomerieux
7.6.1 Biomerieux Comapny Information
7.6.2 Biomerieux Business Overview
7.6.3 Biomerieux Colorectal Cancer Molecular Diagnostics Revenue and Gross Margin (2019-2024)
7.6.4 Biomerieux Colorectal Cancer Molecular Diagnostics Product Portfolio
7.6.5 Biomerieux Recent Developments
7.7 Bio-Rad
7.7.1 Bio-Rad Comapny Information
7.7.2 Bio-Rad Business Overview
7.7.3 Bio-Rad Colorectal Cancer Molecular Diagnostics Revenue and Gross Margin (2019-2024)
7.7.4 Bio-Rad Colorectal Cancer Molecular Diagnostics Product Portfolio
7.7.5 Bio-Rad Recent Developments
7.8 Agilent
7.8.1 Agilent Comapny Information
7.8.2 Agilent Business Overview
7.8.3 Agilent Colorectal Cancer Molecular Diagnostics Revenue and Gross Margin (2019-2024)
7.8.4 Agilent Colorectal Cancer Molecular Diagnostics Product Portfolio
7.8.5 Agilent Recent Developments
7.9 Daangene
7.9.1 Daangene Comapny Information
7.9.2 Daangene Business Overview
7.9.3 Daangene Colorectal Cancer Molecular Diagnostics Revenue and Gross Margin (2019-2024)
7.9.4 Daangene Colorectal Cancer Molecular Diagnostics Product Portfolio
7.9.5 Daangene Recent Developments
7.10 Amoydx
7.10.1 Amoydx Comapny Information
7.10.2 Amoydx Business Overview
7.10.3 Amoydx Colorectal Cancer Molecular Diagnostics Revenue and Gross Margin (2019-2024)
7.10.4 Amoydx Colorectal Cancer Molecular Diagnostics Product Portfolio
7.10.5 Amoydx Recent Developments
8 North America
8.1 North America Colorectal Cancer Molecular Diagnostics Revenue (2019-2030)
8.2 North America Colorectal Cancer Molecular Diagnostics Revenue by Type (2019-2030)
8.2.1 North America Colorectal Cancer Molecular Diagnostics Revenue by Type (2019-2024)
8.2.2 North America Colorectal Cancer Molecular Diagnostics Revenue by Type (2025-2030)
8.3 North America Colorectal Cancer Molecular Diagnostics Revenue Share by Type (2019-2030)
8.4 North America Colorectal Cancer Molecular Diagnostics Revenue by Application (2019-2030)
8.4.1 North America Colorectal Cancer Molecular Diagnostics Revenue by Application (2019-2024)
8.4.2 North America Colorectal Cancer Molecular Diagnostics Revenue by Application (2025-2030)
8.5 North America Colorectal Cancer Molecular Diagnostics Revenue Share by Application (2019-2030)
8.6 North America Colorectal Cancer Molecular Diagnostics Revenue by Country
8.6.1 North America Colorectal Cancer Molecular Diagnostics Revenue by Country (2019 VS 2023 VS 2030)
8.6.2 North America Colorectal Cancer Molecular Diagnostics Revenue by Country (2019-2024)
8.6.3 North America Colorectal Cancer Molecular Diagnostics Revenue by Country (2025-2030)
8.6.4 United States
8.6.5 Canada
9 Europe
9.1 Europe Colorectal Cancer Molecular Diagnostics Revenue (2019-2030)
9.2 Europe Colorectal Cancer Molecular Diagnostics Revenue by Type (2019-2030)
9.2.1 Europe Colorectal Cancer Molecular Diagnostics Revenue by Type (2019-2024)
9.2.2 Europe Colorectal Cancer Molecular Diagnostics Revenue by Type (2025-2030)
9.3 Europe Colorectal Cancer Molecular Diagnostics Revenue Share by Type (2019-2030)
9.4 Europe Colorectal Cancer Molecular Diagnostics Revenue by Application (2019-2030)
9.4.1 Europe Colorectal Cancer Molecular Diagnostics Revenue by Application (2019-2024)
9.4.2 Europe Colorectal Cancer Molecular Diagnostics Revenue by Application (2025-2030)
9.5 Europe Colorectal Cancer Molecular Diagnostics Revenue Share by Application (2019-2030)
9.6 Europe Colorectal Cancer Molecular Diagnostics Revenue by Country
9.6.1 Europe Colorectal Cancer Molecular Diagnostics Revenue by Country (2019 VS 2023 VS 2030)
9.6.2 Europe Colorectal Cancer Molecular Diagnostics Revenue by Country (2019-2024)
9.6.3 Europe Colorectal Cancer Molecular Diagnostics Revenue by Country (2025-2030)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Russia
10 China
10.1 China Colorectal Cancer Molecular Diagnostics Revenue (2019-2030)
10.2 China Colorectal Cancer Molecular Diagnostics Revenue by Type (2019-2030)
10.2.1 China Colorectal Cancer Molecular Diagnostics Revenue by Type (2019-2024)
10.2.2 China Colorectal Cancer Molecular Diagnostics Revenue by Type (2025-2030)
10.3 China Colorectal Cancer Molecular Diagnostics Revenue Share by Type (2019-2030)
10.4 China Colorectal Cancer Molecular Diagnostics Revenue by Application (2019-2030)
10.4.1 China Colorectal Cancer Molecular Diagnostics Revenue by Application (2019-2024)
10.4.2 China Colorectal Cancer Molecular Diagnostics Revenue by Application (2025-2030)
10.5 China Colorectal Cancer Molecular Diagnostics Revenue Share by Application (2019-2030)
11 Asia (Excluding China)
11.1 Asia Colorectal Cancer Molecular Diagnostics Revenue (2019-2030)
11.2 Asia Colorectal Cancer Molecular Diagnostics Revenue by Type (2019-2030)
11.2.1 Asia Colorectal Cancer Molecular Diagnostics Revenue by Type (2019-2024)
11.2.2 Asia Colorectal Cancer Molecular Diagnostics Revenue by Type (2025-2030)
11.3 Asia Colorectal Cancer Molecular Diagnostics Revenue Share by Type (2019-2030)
11.4 Asia Colorectal Cancer Molecular Diagnostics Revenue by Application (2019-2030)
11.4.1 Asia Colorectal Cancer Molecular Diagnostics Revenue by Application (2019-2024)
11.4.2 Asia Colorectal Cancer Molecular Diagnostics Revenue by Application (2025-2030)
11.5 Asia Colorectal Cancer Molecular Diagnostics Revenue Share by Application (2019-2030)
11.6 Asia Colorectal Cancer Molecular Diagnostics Revenue by Country
11.6.1 Asia Colorectal Cancer Molecular Diagnostics Revenue by Country (2019 VS 2023 VS 2030)
11.6.2 Asia Colorectal Cancer Molecular Diagnostics Revenue by Country (2019-2024)
11.6.3 Asia Colorectal Cancer Molecular Diagnostics Revenue by Country (2025-2030)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 China Taiwan
11.6.9 Southeast Asia
12 Middle East, Africa, Latin America
12.1 MEALA Colorectal Cancer Molecular Diagnostics Revenue (2019-2030)
12.2 MEALA Colorectal Cancer Molecular Diagnostics Revenue by Type (2019-2030)
12.2.1 MEALA Colorectal Cancer Molecular Diagnostics Revenue by Type (2019-2024)
12.2.2 MEALA Colorectal Cancer Molecular Diagnostics Revenue by Type (2025-2030)
12.3 MEALA Colorectal Cancer Molecular Diagnostics Revenue Share by Type (2019-2030)
12.4 MEALA Colorectal Cancer Molecular Diagnostics Revenue by Application (2019-2030)
12.4.1 MEALA Colorectal Cancer Molecular Diagnostics Revenue by Application (2019-2024)
12.4.2 MEALA Colorectal Cancer Molecular Diagnostics Revenue by Application (2025-2030)
12.5 MEALA Colorectal Cancer Molecular Diagnostics Revenue Share by Application (2019-2030)
12.6 MEALA Colorectal Cancer Molecular Diagnostics Revenue by Country
12.6.1 MEALA Colorectal Cancer Molecular Diagnostics Revenue by Country (2019 VS 2023 VS 2030)
12.6.2 MEALA Colorectal Cancer Molecular Diagnostics Revenue by Country (2019-2024)
12.6.3 MEALA Colorectal Cancer Molecular Diagnostics Revenue by Country (2025-2030)
12.6.4 Mexico
12.6.5 Brazil
12.6.6 Israel
12.6.7 Argentina
12.6.8 Colombia
12.6.9 Turkey
12.6.10 Saudi Arabia
12.6.11 UAE
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
List of Tables
Table 1. Global Colorectal Cancer Molecular Diagnostics Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
Table 1. Polymerase Chain Reaction PCR Major Manufacturers
Table 2. Molecular Hybridization Major Manufacturers
Table 3. Biochip Major Manufacturers
Table 4. Others Major Manufacturers
Table 5. Global Colorectal Cancer Molecular Diagnostics Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
Table 6. Hospital Major Manufacturers
Table 7. Third-Party Testing Agency Major Manufacturers
Table 8. Others Major Manufacturers
Table 9. Colorectal Cancer Molecular Diagnostics Industry Trends
Table 10. Colorectal Cancer Molecular Diagnostics Industry Drivers
Table 11. Colorectal Cancer Molecular Diagnostics Industry Opportunities and Challenges
Table 12. Colorectal Cancer Molecular Diagnostics Industry Restraints
Table 13. Global Colorectal Cancer Molecular Diagnostics Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
Table 14. Global Colorectal Cancer Molecular Diagnostics Market Size by Region (2019-2024) & (US$ Million)
Table 15. Global Colorectal Cancer Molecular Diagnostics Market Share by Region (2019-2024)
Table 16. Global Colorectal Cancer Molecular Diagnostics Market Size by Region (2025-2030) & (US$ Million)
Table 17. Global Colorectal Cancer Molecular Diagnostics Market Share by Region (2025-2030)
Table 18. Global Colorectal Cancer Molecular Diagnostics Revenue by Players (US$ Million) & (2019-2024)
Table 19. Global Colorectal Cancer Molecular Diagnostics Revenue Market Share by Players (2019-2024)
Table 20. Global Colorectal Cancer Molecular Diagnostics Key Players Ranking, 2022 VS 2023 VS 2024
Table 21. Global Colorectal Cancer Molecular Diagnostics Key Players Headquarters & Area Served
Table 22. Global Colorectal Cancer Molecular Diagnostics Players, Product Type & Application
Table 23. Global Colorectal Cancer Molecular Diagnostics Players Commercialization Time
Table 24. Global Players Market Concentration Ratio (CR5 and HHI)
Table 25. Global Colorectal Cancer Molecular Diagnostics by Players Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2023)
Table 26. Global Colorectal Cancer Molecular Diagnostics Revenue by Type 2019 VS 2023 VS 2030 (US$ Million)
Table 27. Global Colorectal Cancer Molecular Diagnostics Revenue by Type (2019-2024) & (US$ Million)
Table 28. Global Colorectal Cancer Molecular Diagnostics Revenue by Type (2025-2030) & (US$ Million)
Table 29. Global Colorectal Cancer Molecular Diagnostics Revenue Market Share by Type (2019-2024) & (US$ Million)
Table 30. Global Colorectal Cancer Molecular Diagnostics Revenue Market Share by Type (2025-2030) & (US$ Million)
Table 31. Global Colorectal Cancer Molecular Diagnostics Revenue by Application 2019 VS 2023 VS 2030 (US$ Million)
Table 32. Global Colorectal Cancer Molecular Diagnostics Revenue by Application (2019-2024) & (US$ Million)
Table 33. Global Colorectal Cancer Molecular Diagnostics Revenue by Application (2025-2030) & (US$ Million)
Table 34. Global Colorectal Cancer Molecular Diagnostics Revenue Market Share by Application (2019-2024) & (US$ Million)
Table 35. Global Colorectal Cancer Molecular Diagnostics Revenue Market Share by Application (2025-2030) & (US$ Million)
Table 36. Roche Diagnostics Company Information
Table 37. Roche Diagnostics Business Overview
Table 38. Roche Diagnostics Colorectal Cancer Molecular Diagnostics Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 39. Roche Diagnostics Colorectal Cancer Molecular Diagnostics Product Portfolio
Table 40. Roche Diagnostics Recent Development
Table 41. Abbott Company Information
Table 42. Abbott Business Overview
Table 43. Abbott Colorectal Cancer Molecular Diagnostics Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 44. Abbott Colorectal Cancer Molecular Diagnostics Product Portfolio
Table 45. Abbott Recent Development
Table 46. Thermo Fisher Company Information
Table 47. Thermo Fisher Business Overview
Table 48. Thermo Fisher Colorectal Cancer Molecular Diagnostics Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 49. Thermo Fisher Colorectal Cancer Molecular Diagnostics Product Portfolio
Table 50. Thermo Fisher Recent Development
Table 51. Qiagen Company Information
Table 52. Qiagen Business Overview
Table 53. Qiagen Colorectal Cancer Molecular Diagnostics Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 54. Qiagen Colorectal Cancer Molecular Diagnostics Product Portfolio
Table 55. Qiagen Recent Development
Table 56. Illumina Company Information
Table 57. Illumina Business Overview
Table 58. Illumina Colorectal Cancer Molecular Diagnostics Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 59. Illumina Colorectal Cancer Molecular Diagnostics Product Portfolio
Table 60. Illumina Recent Development
Table 61. Biomerieux Company Information
Table 62. Biomerieux Business Overview
Table 63. Biomerieux Colorectal Cancer Molecular Diagnostics Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 64. Biomerieux Colorectal Cancer Molecular Diagnostics Product Portfolio
Table 65. Biomerieux Recent Development
Table 66. Bio-Rad Company Information
Table 67. Bio-Rad Business Overview
Table 68. Bio-Rad Colorectal Cancer Molecular Diagnostics Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 69. Bio-Rad Colorectal Cancer Molecular Diagnostics Product Portfolio
Table 70. Bio-Rad Recent Development
Table 71. Agilent Company Information
Table 72. Agilent Business Overview
Table 73. Agilent Colorectal Cancer Molecular Diagnostics Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 74. Agilent Colorectal Cancer Molecular Diagnostics Product Portfolio
Table 75. Agilent Recent Development
Table 76. Daangene Company Information
Table 77. Daangene Business Overview
Table 78. Daangene Colorectal Cancer Molecular Diagnostics Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 79. Daangene Colorectal Cancer Molecular Diagnostics Product Portfolio
Table 80. Daangene Recent Development
Table 81. Amoydx Company Information
Table 82. Amoydx Business Overview
Table 83. Amoydx Colorectal Cancer Molecular Diagnostics Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 84. Amoydx Colorectal Cancer Molecular Diagnostics Product Portfolio
Table 85. Amoydx Recent Development
Table 86. North America Colorectal Cancer Molecular Diagnostics Revenue by Type (2019-2024) & (US$ Million)
Table 87. North America Colorectal Cancer Molecular Diagnostics Revenue by Application (2019-2024) & (US$ Million)
Table 88. North America Colorectal Cancer Molecular Diagnostics Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 89. North America Colorectal Cancer Molecular Diagnostics Revenue by Country (2019-2024) & (US$ Million)
Table 90. North America Colorectal Cancer Molecular Diagnostics Revenue by Country (2025-2030) & (US$ Million)
Table 91. Europe Colorectal Cancer Molecular Diagnostics Revenue by Type (2019-2024) & (US$ Million)
Table 92. Europe Colorectal Cancer Molecular Diagnostics Revenue by Application (2019-2024) & (US$ Million)
Table 93. Europe Colorectal Cancer Molecular Diagnostics Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 94. Europe Colorectal Cancer Molecular Diagnostics Revenue by Country (2019-2024) & (US$ Million)
Table 95. Europe Colorectal Cancer Molecular Diagnostics Revenue by Country (2025-2030) & (US$ Million)
Table 96. China Colorectal Cancer Molecular Diagnostics Revenue by Type (2019-2024) & (US$ Million)
Table 97. China Colorectal Cancer Molecular Diagnostics Revenue by Application (2019-2024) & (US$ Million)
Table 98. Asia Colorectal Cancer Molecular Diagnostics Revenue by Type (2019-2024) & (US$ Million)
Table 99. Asia Colorectal Cancer Molecular Diagnostics Revenue by Application (2019-2024) & (US$ Million)
Table 100. Asia Colorectal Cancer Molecular Diagnostics Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 101. Asia Colorectal Cancer Molecular Diagnostics Revenue by Country (2019-2024) & (US$ Million)
Table 102. Asia Colorectal Cancer Molecular Diagnostics Revenue by Country (2025-2030) & (US$ Million)
Table 103. MEALA Colorectal Cancer Molecular Diagnostics Revenue by Type (2019-2024) & (US$ Million)
Table 104. MEALA Colorectal Cancer Molecular Diagnostics Revenue by Application (2019-2024) & (US$ Million)
Table 105. MEALA Colorectal Cancer Molecular Diagnostics Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 106. MEALA Colorectal Cancer Molecular Diagnostics Revenue by Country (2019-2024) & (US$ Million)
Table 107. MEALA Colorectal Cancer Molecular Diagnostics Revenue by Country (2025-2030) & (US$ Million)
Table 108. Research Programs/Design for This Report
Table 109. Authors List of This Report
Table 110. Secondary Sources
Table 111. Primary Sources
List of Figures
Figure 1. Colorectal Cancer Molecular Diagnostics Product Picture
Figure 2. Global Colorectal Cancer Molecular Diagnostics Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
Figure 3. Global Colorectal Cancer Molecular Diagnostics Market Size Share 2019 VS 2023 VS 2030
Figure 4. Polymerase Chain Reaction PCR Picture
Figure 5. Molecular Hybridization Picture
Figure 6. Biochip Picture
Figure 7. Others Picture
Figure 8. Global Colorectal Cancer Molecular Diagnostics Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
Figure 9. Global Colorectal Cancer Molecular Diagnostics Market Size Share 2019 VS 2023 VS 2030
Figure 10. Hospital Picture
Figure 11. Third-Party Testing Agency Picture
Figure 12. Others Picture
Figure 13. Global Colorectal Cancer Molecular Diagnostics Market Size (US$ Million) & (2019-2030)
Figure 14. Global Colorectal Cancer Molecular Diagnostics Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 15. Global Colorectal Cancer Molecular Diagnostics Market Share by Region: 2019 VS 2023 VS 2030
Figure 16. Global Colorectal Cancer Molecular Diagnostics Players Revenue Share Top 10 and Top 5 in 2023
Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 18. Global Colorectal Cancer Molecular Diagnostics Revenue by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 19. Global Colorectal Cancer Molecular Diagnostics Revenue Market Share 2019 VS 2023 VS 2030
Figure 20. Global Colorectal Cancer Molecular Diagnostics Revenue Market Share by Type (2019-2030)
Figure 21. Global Colorectal Cancer Molecular Diagnostics Revenue by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 22. Global Colorectal Cancer Molecular Diagnostics Revenue Market Share by Application (2019 VS 2023 VS 2030)
Figure 23. Global Colorectal Cancer Molecular Diagnostics Revenue Market Share by Application (2019-2030)
Figure 24. North America Colorectal Cancer Molecular Diagnostics Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 25. North America Colorectal Cancer Molecular Diagnostics Revenue by Type (2025-2030) & (US$ Million)
Figure 26. North America Colorectal Cancer Molecular Diagnostics Revenue Share by Type (2019-2030)
Figure 27. North America Colorectal Cancer Molecular Diagnostics Revenue by Application (2025-2030) & (US$ Million)
Figure 28. North America Colorectal Cancer Molecular Diagnostics Revenue Share by Application (2019-2030)
Figure 29. North America Colorectal Cancer Molecular Diagnostics Revenue Share by Country (2019-2030)
Figure 30. United States Colorectal Cancer Molecular Diagnostics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 31. Canada Colorectal Cancer Molecular Diagnostics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 32. Europe Colorectal Cancer Molecular Diagnostics Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 33. Europe Colorectal Cancer Molecular Diagnostics Revenue by Type (2025-2030) & (US$ Million)
Figure 34. Europe Colorectal Cancer Molecular Diagnostics Revenue Share by Type (2019-2030)
Figure 35. Europe Colorectal Cancer Molecular Diagnostics Revenue by Application (2025-2030) & (US$ Million)
Figure 36. Europe Colorectal Cancer Molecular Diagnostics Revenue Share by Application (2019-2030)
Figure 37. Europe Colorectal Cancer Molecular Diagnostics Revenue Share by Country (2019-2030)
Figure 38. Germany Colorectal Cancer Molecular Diagnostics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 39. France Colorectal Cancer Molecular Diagnostics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 40. U.K. Colorectal Cancer Molecular Diagnostics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 41. Italy Colorectal Cancer Molecular Diagnostics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 42. Russia Colorectal Cancer Molecular Diagnostics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 43. Nordic Countries Colorectal Cancer Molecular Diagnostics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 44. China Colorectal Cancer Molecular Diagnostics Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 45. China Colorectal Cancer Molecular Diagnostics Revenue by Type (2025-2030) & (US$ Million)
Figure 46. China Colorectal Cancer Molecular Diagnostics Revenue Share by Type (2019-2030)
Figure 47. China Colorectal Cancer Molecular Diagnostics Revenue by Application (2025-2030) & (US$ Million)
Figure 48. China Colorectal Cancer Molecular Diagnostics Revenue Share by Application (2019-2030)
Figure 49. Asia Colorectal Cancer Molecular Diagnostics Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 50. Asia Colorectal Cancer Molecular Diagnostics Revenue by Type (2025-2030) & (US$ Million)
Figure 51. Asia Colorectal Cancer Molecular Diagnostics Revenue Share by Type (2019-2030)
Figure 52. Asia Colorectal Cancer Molecular Diagnostics Revenue by Application (2025-2030) & (US$ Million)
Figure 53. Asia Colorectal Cancer Molecular Diagnostics Revenue Share by Application (2019-2030)
Figure 54. Asia Colorectal Cancer Molecular Diagnostics Revenue Share by Country (2019-2030)
Figure 55. Japan Colorectal Cancer Molecular Diagnostics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 56. South Korea Colorectal Cancer Molecular Diagnostics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 57. India Colorectal Cancer Molecular Diagnostics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 58. Australia Colorectal Cancer Molecular Diagnostics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 59. China Taiwan Colorectal Cancer Molecular Diagnostics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 60. Southeast Asia Colorectal Cancer Molecular Diagnostics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 61. MEALA Colorectal Cancer Molecular Diagnostics Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 62. MEALA Colorectal Cancer Molecular Diagnostics Revenue by Type (2025-2030) & (US$ Million)
Figure 63. MEALA Colorectal Cancer Molecular Diagnostics Revenue Share by Type (2019-2030)
Figure 64. MEALA Colorectal Cancer Molecular Diagnostics Revenue by Application (2025-2030) & (US$ Million)
Figure 65. MEALA Colorectal Cancer Molecular Diagnostics Revenue Share by Application (2019-2030)
Figure 66. MEALA Colorectal Cancer Molecular Diagnostics Revenue Share by Country (2019-2030)
Figure 67. Mexico Colorectal Cancer Molecular Diagnostics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 68. South Korea Colorectal Cancer Molecular Diagnostics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 69. Brazil Colorectal Cancer Molecular Diagnostics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 70. Israel Colorectal Cancer Molecular Diagnostics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 71. Argentina Colorectal Cancer Molecular Diagnostics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 72. Colombia Colorectal Cancer Molecular Diagnostics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 73. Turkey Colorectal Cancer Molecular Diagnostics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 74. Saudi Arabia Colorectal Cancer Molecular Diagnostics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 75. UAE Colorectal Cancer Molecular Diagnostics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 76. Years Considered
Figure 77. Research Process
Figure 78. Key Executives Interviewed
